GeneNews Limited Appoints Floyd C. Dent to its Board of Directors; Reports Earnings Results for the Third Quarter Ended September 30, 2013
November 15, 2013 at 03:26 am IST
Share
GeneNews Limited announced the appointment of Floyd C. Dent to its Board of Directors. Mr. Dent has an accomplished history of strategic sales and marketing management success within the advanced therapeutics and diagnostics areas. Mr. Dent began his business career with Pfizer Inc. after retiring from active service in the U.S. Navy in 1997. Currently, Mr. Dent is a founding partner of a privately-held sales and marketing company in the United States.
The company reported earnings results for the third quarter ended September 30, 2013. For the quarter, the company reported net loss was approximately $3.4 million, or $0.10 loss per common share. This included approximately $1.4 million, or $0.04 per share, in charges related to the Company's previously announced strategic restructuring and approximately $310,000, or $0.01 per share, in costs associated with its share of the initial set-up costs for IDL. In last year's third quarter, net loss was approximately $1.4 million, or $0.07 loss per share. Total revenues were approximately $37,000, a decrease from approximately $158,000 for the same period in 2012. Revenues in 2013 have been negatively impacted by the sales performance of Enzo Clinical Labs Inc., GeneNews' regional marketing partner in New York and New Jersey.
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.